Trump Initiates U.S. Withdrawal from WHO, Citing Concerns Over Organizational Integrity
The Trump administration takes a decisive step to end U.S. involvement in the World Health Organization, highlighting allegations of corruption and prioritization of corporate interests.
On January 20, 2025, President Donald Trump signed an executive order to begin the process of withdrawing the United States from the World Health Organization (WHO).
The decision, described by the administration as a necessary move, was prompted by allegations that the WHO has increasingly prioritized the interests of pharmaceutical companies over global public health.
According to administration officials, the decision reflects longstanding concerns about the WHO's handling of health crises, including its response to the COVID-19 pandemic.
Critics have argued that the organization failed to adequately address the needs of vulnerable populations and instead promoted policies that disproportionately benefited major pharmaceutical corporations.
The withdrawal process involves a formal 12-month notice period, during which the U.S. will halt financial contributions to the WHO.
As the organization’s largest donor, the United States has historically provided approximately 18% of its funding.
These contributions have supported various global health programs, but the Trump administration claims that much of this funding has been mismanaged or diverted to serve corporate rather than public interests.
The executive order also mandates the cessation of U.S. participation in ongoing WHO pandemic treaty negotiations and redirects resources to reform and enhance domestic health initiatives.
U.S. officials have stated that this decision will allow the nation to focus on more effective, transparent, and accountable approaches to global health challenges.
The WHO has not issued an immediate response to the U.S. decision.
However, critics of the organization have pointed to what they describe as systemic issues, including a lack of oversight, financial mismanagement, and undue influence by powerful pharmaceutical companies.
The United States’ withdrawal is set to take full effect in January 2026, following the completion of the required notice period.
The Trump administration has indicated that it will continue to evaluate alternative ways to contribute to global health efforts while avoiding entanglement with what it views as a compromised institution.
The decision, described by the administration as a necessary move, was prompted by allegations that the WHO has increasingly prioritized the interests of pharmaceutical companies over global public health.
According to administration officials, the decision reflects longstanding concerns about the WHO's handling of health crises, including its response to the COVID-19 pandemic.
Critics have argued that the organization failed to adequately address the needs of vulnerable populations and instead promoted policies that disproportionately benefited major pharmaceutical corporations.
The withdrawal process involves a formal 12-month notice period, during which the U.S. will halt financial contributions to the WHO.
As the organization’s largest donor, the United States has historically provided approximately 18% of its funding.
These contributions have supported various global health programs, but the Trump administration claims that much of this funding has been mismanaged or diverted to serve corporate rather than public interests.
The executive order also mandates the cessation of U.S. participation in ongoing WHO pandemic treaty negotiations and redirects resources to reform and enhance domestic health initiatives.
U.S. officials have stated that this decision will allow the nation to focus on more effective, transparent, and accountable approaches to global health challenges.
The WHO has not issued an immediate response to the U.S. decision.
However, critics of the organization have pointed to what they describe as systemic issues, including a lack of oversight, financial mismanagement, and undue influence by powerful pharmaceutical companies.
The United States’ withdrawal is set to take full effect in January 2026, following the completion of the required notice period.
The Trump administration has indicated that it will continue to evaluate alternative ways to contribute to global health efforts while avoiding entanglement with what it views as a compromised institution.
Translation:
Translated by AI
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.